Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa
Retrieved on:
Friday, February 10, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, South African Class MG 2-6-6-2, CK, Inflammation, Acne, Drug development, Abstract, Week, Upper respiratory tract infection, Safety, Patient, Common, Urinary tract infection, Associate, Hidradenitis suppurativa, JAK1, Autoimmunity, Conference, COVID-19, HS, Headache, Pharmaceutical industry, Abscess
Incyte (Nasdaq:INCY) today announced new 52-week results from a Phase 2 study evaluating the efficacy and safety of povorcitinib (formerly INCB54707), an oral JAK1 inhibitor, in adult patients with hidradenitis suppurativa (HS).
Key Points:
- Incyte (Nasdaq:INCY) today announced new 52-week results from a Phase 2 study evaluating the efficacy and safety of povorcitinib (formerly INCB54707), an oral JAK1 inhibitor, in adult patients with hidradenitis suppurativa (HS).
- These data were presented as an oral presentation (Abstract #258) at the 12th Conference of the European Hidradenitis Suppurativa Foundation, held from February 8-10, 2023, in Florence, Italy.
- Povorcitinib was generally well tolerated and the safety profile was consistent with previously-reported data.
- We look forward to continuing to progress the development of povorcitinib through our ongoing Phase 3 trial in patients with moderate-to-severe HS.”
Additional 52-week efficacy results include: